


Myocardial Infarction Market Size is Anticipated to Increase at a CAGR of 1.61% During the Study Period (2019-2032)

Myocardial Infarction Market

LAS VEGAS, NEVADA, UNITED STATES, March 27, 2024 /EINPresswire.com/ -- DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.



Key Takeaways from the Myocardial Infarction Market Research Report

- As per DelveInsight analysis, the Myocardial Infarction market size in the 7MM was approximately USD 21 billion in 2021
- According to the assessment done by DelveInsight, the estimated total Myocardial Infarction diagnosed prevalent cases in the 7MM was approximately 15 million in 2021
- The leading Myocardial Infarction companies such as AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others are developing novel MI drugs that can be available in the MI market in the coming years
- The promising Myocardial Infarction pipeline therapies in the various stages of development include FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Olpasiran (AMG860), Pelacarsen (TQJ230), Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC, and others.
- March 2024: Cardior Pharmaceuticals GmbH announced a study of Phase 2 clinical trials for CDR132L. This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) ($\leq 45\%$) after myocardial infarction (MI). This study consists of a screening period (to occur

at least 3 days after MI diagnosis), a 6-month double-blind period, and a 6-month extension period with the End of Study (EOS) Visit at Day 360/Month 12.

- March 2024: Boehringer Ingelheim announced a study of Phase 2 clinical trials for BI 765845. This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack. The investigators also want to test how well different doses of BI 765845 work and how they are tolerated by people who have had a heart attack.

Discover which therapies are expected to grab the Myocardial Infarction market share @ [Myocardial Infarction Market Outlook](#)

Myocardial Infarction Overview

A myocardial infarction, commonly known as a heart attack, occurs when the flow of blood to the heart is severely reduced or blocked. This blockage usually results from a buildup of fat, cholesterol, and other substances in the coronary arteries. These fatty deposits, called plaques, can rupture, leading to the formation of a blood clot that obstructs blood flow. As a consequence, part of the heart muscle may become damaged or die. Prompt treatment is crucial to prevent fatalities. Common symptoms include chest pain, which may radiate to the shoulder, arm, back, neck, or jaw, along with cold sweat, fatigue, and shortness of breath.

Myocardial Infarction Epidemiology Segmentation in the 7MM

- Myocardial Infarction Diagnosed Prevalent Cases
- Myocardial Infarction Gender-specific Prevalence
- Myocardial Infarction Type-specific Prevalence

Download the report to understand which factors are driving Car Myocardial Infarction epidemiology trends @ [Myocardial Infarction Epidemiological Insights](#)

Myocardial Infarction Drug Market

The current Myocardial Infarction drug market has been segmented into different commonly used therapeutic classes based on the prevailing MI treatment pattern across the 7MM, which exhibits minor variations in the overall prescription pattern. The major classes covered in the forecast model are antiplatelet agents, anticoagulants, vasodilators, beta-blockers, lipid-lowering drugs, Angiotensin-converting enzyme (ACE) inhibitors, ARBs (Angiotensin-II receptor Blockers), and calcium channel blockers.

Myocardial Infarction Market Dynamics

The Myocardial Infarction market dynamics is anticipated to change in the coming years. The growing emphasis on secondary preventive measures to avoid recurrent/new events, lifestyle changes, and the growing number of smokers and cases of obesity, diabetes, hypertension, and others, are expected to fuel MI market growth. Moreover, heart attacks and strokes are major cost drivers in the 7MM healthcare system. The volume of the Myocardial Infarction market is enormous. The patient is receiving multiple therapies at the same time. The smallest portion of

the patient share can provide pharmaceutical companies with options worth millions of dollars in the Myocardial Infarction market.

MI Pipeline Therapies and Companies

- FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
- JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company
- Pelacarsen (TQJ230): Novartis
- Olpasiran: Amgen
- Selatogrel: Idorsia Pharmaceuticals
- FDY-5301: Faraday Pharmaceuticals
- CSL112: CSL Behring
- IMT-358: Immediate Therapeutics
- CL2020: Mitsubishi Chemical Group
- MEDI6570: AstraZeneca
- KAND567: Kancera
- Asundexian: Bayer
- Dutogliptin: Recardio
- MPC-25-IC: Mesoblast

Myocardial Infarction Treatment Landscape

The goals of initial Myocardial Infarction treatment are to relieve pain, immediately identify ST changes via 12-lead EKG, initiate reperfusion (if the patient is a candidate), and assess and treat hemodynamic abnormalities. Oxygen, nitroglycerin, and morphine sulfate are the most effective pain relievers. Reperfusion therapy is indicated for patients with ST-segment elevation or a new LBBB with symptoms lasting 12 hours or less. MI treatment may be divided into two paths depending on whether the patient has a STEMI or an NSTEMI. The pharmacologic MI treatment is further subdivided into several groups of medications that improve survival, reduce recurrent ischemic events, and provide symptomatic relief. Following the primary Myocardial Infarction treatment, a multimodal regimen of therapies is used. To classify the disease, rapid diagnostic tests and serial biomarker analysis are used to begin MI treatment.

Scope of the Myocardial Infarction Market Report

- Coverage- 7MM
- Study Period- 2019-2032
- Myocardial Infarction Companies- AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others.
- Myocardial Infarction Pipeline Therapies- FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Olpasiran (AMG860), Pelacarsen (TQJ230), Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC, and others
- Myocardial Infarction Market Dynamics: Myocardial Infarction Market Drivers and Barriers

Discover more about Myocardial Infarction Drugs in development @ [Myocardial Infarction Ongoing Clinical Trials Analysis](#)

Table of Content

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Myocardial Infarction Market Overview at a Glance
7. Disease Background and Overview
8. Treatment and Management
9. Guidelines and Recommendations for MI
10. Epidemiology and Patient Population of Myocardial infarction (MI) in the 7MM
11. Patient Journey
12. Marketed Therapies
13. Emerging Therapies
14. Myocardial infarction (MI): 7MM Analysis
15. Unmet Needs
16. SWOT Analysis
17. KOL Views
18. Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 96502 13330
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/699139049>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.